Hepatotoxicity related to intracavernous pharmacotherapy with papaverine

Urology

Volumn 52, Issue 5, 1998, Pages 844-847

  Brown, Scott L ^a   Haas, Christopher A ^a   Koehler, Michael ^b   Bodner, Donald R ^a   Seftel, Allen D ^a  

^a Dept Gastroenterol Cleveland V ^*  (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PAPAVERINE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FOLLOW UP; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL;

ADULT; AGED; FOLLOW-UP STUDIES; HEPATITIS, TOXIC; HUMANS; IMPOTENCE; INCIDENCE; MALE; MIDDLE AGED; PAPAVERINE; PENIS; PHENTOLAMINE; RETROSPECTIVE STUDIES; VASODILATOR AGENTS;

EID: 0031795737     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00290-8     Document Type: Article

References (19)

1. Bennett A.H. Management of Male Impotence. 1982;Williams & Wilkins, Baltimore.
2. Impotence. NIH Consensus Statement, December 7-9, Vol 10, No. 4, pp 1-31, 1992.
3. Brindley G.S. Cavernosal alpha-blockade a new technique for investigating and treating erectile impotence . Br J Psychiatry. 143:1983;332-337.
4. Bell D.S., Cutter G.R., Hayne V.B., et al. Factors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in diabetic male. Urology. 40:1992;36-40.
5. 1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erectile dysfunction Review of the literature . Actas Urol Esp. 16:1992;208-216.
6. 1 and papaverine in treatment of erectile failure double-blind crossover study among Egyptian patients . J Urol. 147:1992;623-626.
7. 1 in erectile dysfunction. Urologe A. 28:1989;94-98.
8. 1 in the therapy of erectile dysfunction. Vasa. 28:(suppl):1989;50-56.
9. 1 in impotent men. J Urol. 140:1988;66-68.
10. 1 for diagnosis and treatment of erectile dysfunction. World J Urol. 8:1990;84.
11. Turner L.A., Althof S.E., Levine S.B., et al. Twelve-month comparison of two treatments for erectile dysfunction self-injection versus external vacuum devices . Urology. 39:1992;139-144.
12. Sidi A.A. Vasoactive intracavernous pharmacotherapy. Urol Clin North Am. 15:1988;95-101.
13. van Ahlen H., Peskar B.A., Sticht G., et al. Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J Urol. 151:1994;1227-1230.
14. Levine S.B., Althof S.E., Turner L.A., et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol. 141:1989;54-57.
15. Ronnov-Jessen V., Tjerlund A. Hepatotoxicity due to treatment with papaverine. N Engl J Med. 281:1969;1333-1335.
16. Drieman P.M. Papaverine - hepatotoxic or not? J Am Geriat Soc. 21:1973;202-205.
17. Lakin M.M., Montague D.K., Vanderbrug Medendorp S., et al. Intracavernous injection therapy analysis of results and complications . J Urol. 143:1990;1138-1141.
18. Kraus C., Shaaya A., Ulmer J., et al. Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs. Biopharm Drug Dispos. 12:1991;537-546.
19. Ritschel W.A., Kraus C., Shaaya A., et al. Pharmacokinetics of papaverine HCl upon intravenous route of administration in old and young beagle dogs. Methods Find Exp Clin Pharmacol. 13:1991;51-55.